Atara Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atara Biotherapeutics (ATRA).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

3Buy

4Hold

1Sell

Consensus RatingBuy# Analysts8Avg. Consensus PT$22Upside to Avg. PT+142.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 18, 2026	Freedom Broker	Ilya Zubkov	Upgrade	Sell→Hold	$4→$10
May 8, 2026	Canaccord Genuity	John Newman	Upgrade	Hold→Buy	$6→$13
Jan 21, 2026	Freedom Broker	Ilya Zubkov	Downgrade	Buy→Sell	$16→$4
Jan 13, 2026	Canaccord Genuity	John Newman	Downgrade	Buy→Hold	$25→$6
Dec 19, 2025	Canaccord Genuity	John Newman	PT Raise	Buy	$17→$25
Jul 28, 2025	Freedom Broker	Ilya Zubkov	PT Raise	Sell	$13→$16
May 23, 2025	Freedom Broker	Ilya Zubkov	PT Raise	Sell	$11→$13
Mar 13, 2025	Freedom Broker	Ilya Zubkov	PT Cut	Sell	$13→$11
Mar 11, 2025	Canaccord Genuity	John Newman	Maintained	Buy	$17
Jan 28, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Jan 22, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Jan 17, 2025	Canaccord Genuity	John Newman	PT Cut	Buy	$21→$17
Dec 20, 2024	Rodman & Renshaw	Tony Butler	Initiate	Buy	$25
Nov 13, 2024	Canaccord Genuity	John Newman	PT Raise	Buy	$13→$21
Aug 21, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Aug 16, 2024	Mizuho	Salim Syed	Upgrade	Neutral→Outperform	$25→$18
Aug 13, 2024	Canaccord Genuity	John Newman	Maintained	Buy	$13
Jul 17, 2024	Goldman Sachs	Tommie Reerink	PT Cut	Sell	$13→$11
May 22, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	—
Apr 1, 2024	Stifel	Benjamin Burnett	PT Cut	Hold	$5→$2

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.

Benzinga Newsdesk

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

Canaccord Genuity analyst John Newman downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $25 to $6.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and raises the price target from $17 to $25.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

Benzinga Newsdesk

Atara Biotherapeutics Inc

Atara Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

People Also Watch

People Also Watch

Atara Biotherapeutics Inc

Atara Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCanaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

PROCanaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

PROCanaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

PROCanaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

PROHC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

PROHC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

People Also Watch

People Also Watch

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral